BioMark Closes Final Tranche of Private Placement Offering

October 4th, 2018 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of September 20, 2017, it has closed the final tranche of a non-brokered private placement for gross proceeds of $222,100.00 wherein BioMark issued 2,221,000 units at a price of $ 0.10 per unit.


Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.15 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause. No Finders’ fees were payable on the private placement.


The proceeds of the private placement will be used for the continuation of the Company’s regulatory submission costs, patent costs, sample acquisition costs and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.


Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement constitutes a related party transaction as defined under Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). Because the Company’s shares trade only on the CSE, the issuance of securities is exempt from the formal valuation requirements of Section 5.4 of MI 61-101 pursuant to Subsection 5.5(b) of MI 61-101 and exempt from the minority approval requirements of Section 5.6 of MI 61-101. The Company did not file a material change report 21 day prior to the closing of the private placement as the details of the participation of insiders of the Company had not been confirmed at that time.

Press Release – Biomark Closes Final Tranche of Private Placement Offering – Oct 4, 2018

Share this post:

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.